Gemcitabine/Cisplatin

DRUG10 trials

Sponsors

Spanish Lung Cancer Group, Guangdong Association of Clinical Trials, Tongji University, Kansai Hepatobiliary Oncology Group, Shanghai Jiao Tong University School of Medicine

Conditions

Androgen Receptor PositiveBiliary Tract CancerNasopharyngeal CarcinomaNon-small Cell Lung CancerNon-small-cell Lung CancerRecurrent Non-small Cell Lung CancerUpper Tract Urothelial CarcinomaUrothelial Carcinoma Bladder

Phase 1

A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer

RecruitingNCT02889666

Shanghai Jiao Tong University School of MedicineRecurrent Non-small Cell Lung Cancer

Start: 2008-01-31End: 2027-12-31Target: 500Updated: 2024-04-17

Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant

TerminatedNCT05839119

Brown UniversityAndrogen Receptor Positive, Urothelial Carcinoma Bladder

Start: 2023-10-02End: 2025-10-17Updated: 2026-04-02

Phase 2

Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer

Guangdong Association of Clinical TrialsNon-small Cell Lung Cancer

Start: 2011-12-05End: 2022-12-31Updated: 2018-09-11

Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC)

Tongji UniversityNon-small Cell Lung Cancer

Start: 2010-12-31End: 2014-12-31Target: 120Updated: 2014-09-25

Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma

The European Uro-Oncology GroupUpper Tract Urothelial Carcinoma

Start: 2018-05-28End: 2025-12-31Target: 200Updated: 2023-12-18

Phase 3

Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)

CompletedNCT00478699

Spanish Lung Cancer GroupNon-small-cell Lung Cancer

Start: 2007-06-30End: 2015-07-31Updated: 2024-12-12

GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer

CompletedNCT02182778

Kansai Hepatobiliary Oncology GroupBiliary Tract Cancer

Start: 2014-07-09End: 2018-04-16Updated: 2019-02-21

Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Nasopharyngeal Carcinoma

Start: 2018-08-27End: 2021-07-30Target: 336Updated: 2019-02-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Active, not recruitingNCT06109779

AstraZenecaBiliary Tract Cancer

Start: 2023-12-04End: 2030-05-03Updated: 2026-03-04

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

RecruitingNCT07221253

AstraZenecaBiliary Tract Cancer

Start: 2025-12-04End: 2029-07-04Target: 1100Updated: 2026-03-17

Related Papers

A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01.

Journal of Clinical Oncology2024-06-015 citations

Abstract CT085: Targeting androgen signaling in urothelial carcinoma

Cancer Research2024-04-05

Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial.

2023-02-2456 citations

Randomized phase <scp>III</scp> study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (<scp>KHBO1401</scp>‐ <scp>MITSUBA</scp>)

Journal of Hepato-Biliary-Pancreatic Sciences2022-07-28224 citations

Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study

Journal of Clinical Oncology2021-08-1194 citations

CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non–small cell lung cancer.

Journal of Clinical Oncology2021-05-2026 citations

Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.

2020-03-05359 citations

A multicenter, randomized, double-blind, placebo-controlled phase III study of anlotinib or placebo in combination with gemcitabine and cisplatin (GP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).

Journal of Clinical Oncology2019-05-201 citations

Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)

Annals of Oncology2018-10-01108 citations

Histological complete response in a patient with advanced biliary tract cancer treated by gemcitabine/cisplatin/S-1 combination chemotherapy: A case report

Molecular and Clinical Oncology2016-10-2612 citations

Randomised phase III study of gemcitabine, cisplatin plus S-1 (GCS) compared with gemcitabine plus cisplatin (GC) for unresectable or recurrent biliary tract cancer (KHBO1401-MITSUBA).

Journal of Clinical Oncology2015-05-201 citations

Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Journal of Hematology & Oncology2015-05-1687 citations

A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).

2014-12-0542 citations